Introduction
The advent of highly active antiretroviral therapy (HAART) has significantly altered the course of HIV disease, producing substantial reductions in both AIDS-related morbidity and mortality. 1, 2 However, these advances have emerged amid growing concerns regarding low levels of adherence among selected populations, including injection drug users (IDUs). 3, 4 Adherence has been strongly associated with suppression of HIV and survival in many settings, 1,2 and therefore, considerable effort has been dedicated to developing measures of adherence to HAART. 5 Although various measures of self-reported adherence have been found to be associated with HIV-related clinical outcomes, 6 there have been few Background: In Vancouver, the availability of prescription refill data for all HIV-infected individuals plus a prospective cohort of injection drug users (IDUs) permitted an examination of the validity of self-reported highly active antiretroviral therapy (HAART) adherence among IDUs. Methods: Self-reported HAART adherence among Vancouver Injection Drug Users Study participants was compared with pharmacy refill rates from the British Columbia Drug Treatment Program database. Pearson's correlation coefficient and Pearson's χ 2 test were used to assess associations between adherence as measured by self-report and pharmacy refill data. Results: Among 88 HIV-infected IDUs, 48 (55%) had an adherence rate of ≥75% as measured by pharmacy refill adherence, whereas 81 (92%) had an adherence rate of ≥75% as measured by self-report. Self-reported adherence was not statistically associated with pharmacy refill adherence (P > .1). Conclusion: These findings suggest that the validity of self-report measures may be limited when applied to community-recruited IDUs. DTP distributes antiretroviral agents at no cost to eligible HIV-infected individuals in the province of British Columbia. 7 All HAART medications are stored within a centralized pharmacy, and the DTP maintains records of all medications that are dispensed. In Vancouver, pharmacy refill adherence has been used extensively and shown to be associated with viral suppression 8 and has also been strongly associated with viral suppression and CD4 T-cell count response among IDUs. 7, 9 For the present study, we developed a self-report measure of adherence. Participants were asked: "In the last 6 months, how often did you take your medications as prescribed?" Possible responses included: "always (100%)," "usually (more than 75%)," "sometimes (26-74%)," "occasionally (less than 25%)," and "never." To calculate pharmacy refill adherence over the same 6-month period, the number of days for which medications were supplied was divided by the number of days for which medications were prescribed. Pearson's correlation coefficient and Pearson's χ 2 test were used to assess associations between adherence as measured by self-report and pharmacy refill data. A 75% adherence cutoff was used in these analyses because this cutoff has been shown previously to predict survival among HIV-infected patients. 10 Analyses were performed using SPSS 10.0. All P values are 2 sided.
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Results
In total, 88 participants were eligible for the present analyses. Of these participants, 49 (56%) were men and 39 (44%) were women. The mean age was 40 years (standard deviation = 6.8). In total, 48 (55%) participants had an adherence rate of 75% or greater as measured by pharmacy refill adherence, whereas 81 (92%) had an adherence rate of 75% or greater as measured by self-report. When the adherence measures were considered as continuous variables, the correlation between pharmacy refill adherence and self-reported adherence was r = −0.06, P = .57. The univariate association between 75% adherence as measured by pharmacy refill and self-report was nonsignificant (odds ratio = 1.66, 95% confidence interval = 0.35-7.90, P = .52).
Discussion
Our study has several limitations. First, like most other cohort studies involving IDUs, VIDUS is not a random sample. Second, although it is recognized that pharmacy refill adherence likely overestimates adherence because individuals may pick up prescriptions but then not take all the prescribed doses, it is notable that this measure of adherence has been strongly associated with HIV-related clinical outcomes among IDUs, including viral suppression and mortality. 7, 9 It should also be noted that IDUs in this study reported substantially higher levels of adherence via self-report. Furthermore, because all antiretroviral medications are administered through a central location, it is not possible to obtain an adherence score that is higher than that determined through pharmacy refill data. Also, it should be pointed out that there is currently no "gold standard" measure of adherence. 5 Third, there are many different self-report measures in use, 6 and other self-report measures may have produced stronger associations with pharmacy refill adherence than the one used in the present study.
In summary, we found that HAART adherence among IDUs as measured by self-report greatly overestimated adherence that could be conservatively estimated through pharmacy refills. This finding is consistent with a previous study from our setting suggesting that major discrepancies exist between self-report and pharmacy-based measures of antiretroviral use among IDUs. 11 This may be because of various factors, such as socially desirable responding or recall bias arising from memory problems common among IDUs, including those related to ongoing drug use and psychiatric comorbidities. 12, 13 These findings suggest that although self-report measures may be of considerable utility in research and clinical settings, 6 the validity of this type of measure may be limited when applied to community-recruited IDUs.
